Cookies show us what works. Privacy
Cookies show us what works. Privacy
AstraZeneca (AZN) has not announced its next earnings date. The next report covers the quarter ending Dec 31, 2026. A year earlier it reported the same quarter on Feb 10, 2026. Analysts expect earnings per share of $1.74 (1 analysts) on revenue of $16.6B.
Last report, Oct 30, 2026: EPS $2.79 against $2.60 expected (+7.3%). The stock moved 0.0% the next day. Beat the EPS estimate in 6 of the last 7 reports. The stock moved 1.7% on average the next day, up or down; the largest move was +5.9%.
| Reported | Quarter ended | EPS | Estimate | Surprise | Next day |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | $2.79 | $2.60 | +7.3% | 0.0% |
| Jul 27, 2026 | Jun 30, 2026 | $2.63 | $2.50 | +5.2% | +1.7% |
| Apr 29, 2026 | Mar 31, 2026 | $1.29 | $1.27 | +1.6% | +1.2% |
| Feb 10, 2026 | Dec 31, 2025 | $1.49 | - | - | +5.9% |
| Nov 6, 2025 | Sep 30, 2025 | $1.19 | $1.13 | +5.3% | +1.0% |
| Jul 29, 2025 | Jun 30, 2025 | $0.79 | $0.88 | -10.2% | +3.5% |
| Apr 29, 2025 | Mar 31, 2025 | $1.25 | $1.12 | +11.6% | +0.1% |
| Feb 6, 2025 | Dec 31, 2024 | $1.05 | $1.04 | +1.0% | -0.5% |
AstraZeneca (AZN) has not announced its next earnings date. The next report covers the quarter ending Dec 31, 2026. A year earlier it reported the same quarter on Feb 10, 2026.
$1.74 a share, the average of 1 analysts, for the quarter ending Dec 31, 2026. The revenue estimate is $16.6B.
Yes. Last report, Oct 30, 2026: EPS $2.79 against $2.60 expected (+7.3%). The stock moved 0.0% the next day.
Report dates come from the Alpha Vantage earnings calendar and stay expected until the company confirms them. EPS is as reported against the analyst average; the next-day move is close to close. Not investment advice.